EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Cannabinol for Acute Treatment of Insomnia Disorder in a Randomized Placebo‐Controlled Crossover Trial

Isobel G Lavender iD, Nathaniel S Marshall iD, Danielle McCartney iD, Garry Cho iD, Chris Irwin, Anastasia Suraev iD, Rebecca Gordon, Jonathon C Arnold iD, Angela L D'Rozario iD, Christopher J Gordon iD, Bandana Saini iD, Sheila Sivam iD und 5 weitere

Journal of Sleep Research · 2026-08 · 35 (4)

DOI: 10.1111/jsr.70284 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Sleep Research, online erschienen am 16.02.2026. Verfasst von Isobel G Lavender und 16 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Sleep and Chronobiology, Woolcock Institute of Medical Research, Macquarie University, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Sleep Initiation and Maintenance Disorders, Hypnotics and Sedatives. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: The Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, University of Sydney Postgraduate Award Stipend and Barry and Joy Lambert Postgraduate Research Scholarship, National Heart Foundation Future Leader Fellowship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Insomnia disorder is harmful and requires novel treatments. Cannabinol, an oxidative by‐product of Δ9‐tetrahydrocannabinol, is claimed to be a hypnotic, but its effects on objective sleep and insomnia remain unknown. This randomized, double‐blind, placebo‐controlled, three‐arm, single‐night crossover trial evaluated the acute efficacy and safety of cannabinol for insomnia disorder. Twenty adults (aged 25–65) with physician‐diagnosed insomnia disorder (meeting DSM‐5 and ICSD‐3 criteria; Insomnia Severity Index ≥ 15) were enrolled at the Woolcock Institute of Medical Research (Sydney, Australia) between August 2022 and September 2023. Participants received a single 2 mL oral dose of 30 mg (1.5%) or 300 mg (15%) cannabinol, or matched placebo (2‐week washout). All participants (17 female and 3 males; mean ± SD age 42 ± 13 years) completed the protocol and were statistically analysed. The primary outcome was wake after sleep onset (WASO) minutes, measured by overnight polysomnography. Cannabinol did not significantly change WASO (300 mg: −6.3 min [95% CI: −18.2, +5.5], p = 0.29, dz = −0.22; 30 mg: −4.0 min [−15.9, +7.9], p = 0.50, dz = 0.11). However, 300 mg cannabinol increased non‐rapid eye movement‐2 sleep ( p = 0.03, dz = 0.54), subjective sleep quality ( p = 0.005, dz = 0.56); and reduced sleep onset latency ( p = 0.004, dz = −0.74) and electroencephalographic arousal indices ( p = 0.02, dz = −0.65). There were 247 mild‐to‐moderate adverse events across arms. Larger, longer trials are warranted. ClinicalTrials.gov Identifier: NCT05344170.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sleep Initiation and Maintenance DisordersHypnotics and SedativesHumansCross-Over StudiesDouble-Blind MethodFemalePolysomnographyAdultMiddle AgedMaleTreatment OutcomeAged

Stichwörter der Autor:innen

cannabinoidselectroencephalographyneurobehavioral functionpolysomnographypower spectral analysis

Substanzen

Hypnotics and Sedatives

Autor:innen und Institutionen

  • Centre for Sleep and Chronobiology, Woolcock Institute of Medical Research, Macquarie University, Sydney, New South Wales, Australia.
  • School of Psychology, Faculty of Science, The University of Sydney, Sydney, New South Wales, Australia.
  • Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney, Sydney, New South Wales, Australia.
  • Department of Health Science, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia.
  • School of Health Sciences and Social Work, Griffith University, Gold Coast, Queensland, Australia.
  • Discipline of Pharmacology, Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.

ORCID-Profile: Isobel G Lavender, Nathaniel S Marshall, Danielle McCartney, Garry Cho, Anastasia Suraev, Jonathon C Arnold, Angela L D'Rozario, Christopher J Gordon, Bandana Saini, Sheila Sivam, Yizhong Zheng, Ronald R Grunstein, Brendon J Yee, Iain S McGregor, Camilla M Hoyos

Förderung

  • The Lambert Initiative for Cannabinoid Therapeutics, Brain and Mind Centre, The University of Sydney
  • University of Sydney Postgraduate Award Stipend and Barry and Joy Lambert Postgraduate Research Scholarship
  • National Heart Foundation Future Leader Fellowship
  • National Health and Medical Research Council-Australian (NHMRC) Investigator Grants
  • National Health and Medical Research Council

Zitieren

APA

Lavender, I. G., Marshall, N. S., McCartney, D., Cho, G., Irwin, C., Suraev, A., Gordon, R., Arnold, J. C., D'Rozario, A. L., Gordon, C. J., Saini, B., Sivam, S., Zheng, Y., Grunstein, R. R., Yee, B. J., McGregor, I. S., & Hoyos, C. M. (2026). Cannabinol for Acute Treatment of Insomnia Disorder in a Randomized Placebo‐Controlled Crossover Trial. Journal of Sleep Research, 35(4). https://doi.org/10.1111/jsr.70284

Vancouver

Lavender IG, Marshall NS, McCartney D, Cho G, Irwin C, Suraev A, et al. Cannabinol for Acute Treatment of Insomnia Disorder in a Randomized Placebo‐Controlled Crossover Trial. Journal of Sleep Research. 2026;35(4). doi:10.1111/jsr.70284

BibTeX
@article{Lavender2026,
  author = {Lavender, Isobel G and Marshall, Nathaniel S and McCartney, Danielle and Cho, Garry and Irwin, Chris and Suraev, Anastasia and Gordon, Rebecca and Arnold, Jonathon C and D'Rozario, Angela L and Gordon, Christopher J and Saini, Bandana and Sivam, Sheila and Zheng, Yizhong and Grunstein, Ronald R and Yee, Brendon J and McGregor, Iain S and Hoyos, Camilla M},
  title = {Cannabinol for Acute Treatment of Insomnia Disorder in a Randomized Placebo‐Controlled Crossover Trial},
  journal = {Journal of Sleep Research},
  year = {2026},
  volume = {35},
  number = {4},
  doi = {10.1111/jsr.70284}
}
Kostenlos starten →